Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.71 |
| ▸ | CX3CR1 | P49238 | 3/20 | 0.67 |
| ▸ | HTR1B | P28222 | 1/20 | 0.59 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.57 |
| ▸ | CCR7 | P32248 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4693395 | 0.99 | CXCR2 (0.70) | CXCR2CX3CR1HTR1BCXCR1CCR7 | |
| SCHEMBL4693389 | 0.99 | CXCR2 (0.70) | CXCR2CX3CR1HTR1BCXCR1CCR7 | |
| SCHEMBL842340 | 0.93 | CXCR2 (0.71) | CXCR2CX3CR1HTR1BCXCR1CCR7 | |
| SCHEMBL13140053 | 0.91 | CXCR2 (0.70) | CXCR2CX3CR1HTR1BCXCR1CCR7 | |
| SCHEMBL842296 | 0.84 | CXCR2 (0.72) | CXCR2CX3CR1HTR1BCXCR1CCR7 | |
| SCHEMBL841899 | 0.83 | CXCR2 (1.00) | CXCR2CX3CR1HTR1B | |
| SCHEMBL842524 | 0.83 | CXCR2 (0.86) | CXCR2CX3CR1HTR1B | |
| SCHEMBL841616 | 0.83 | CXCR2 (0.98) | CXCR2CX3CR1HTR1B | |
| SCHEMBL841617 | 0.83 | CXCR2 (0.98) | CXCR2CX3CR1HTR1B | |
| SCHEMBL4711342 | 0.82 | CXCR2 (0.83) | CXCR2CX3CR1HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100217000-A1 | Process for the Preparation of Thiazolopyrimidines | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | claimed |
| US-20090043097-A1 | Methods | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | claimed |
| EP-1543013-B1 | 5-[[(2,3-Difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one monosodium salt as CXCR2 antagonist | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | EP | claimed |
| US-20070282103-A1 | Process for the Preparation of Thiazolopyrimidines | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | claimed |
| US-7790883-B2 | Process for the preparation of thiazolopyrimidines | ASTRAZENECA AB (SE) | 2010-09-07 | — | — | US | disclosed |
| US-7790883-B2 | Process for the preparation of thiazolopyrimidines | ASTRAZENECA AB (SE) | 2010-09-07 | — | — | US | disclosed |
| US-7790883-B2 | Process for the preparation of thiazolopyrimidines | ASTRAZENECA AB (SE) | 2010-09-07 | — | — | US | disclosed |
| US-20100217000-A1 | Process for the Preparation of Thiazolopyrimidines | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | disclosed |
| US-20100217000-A1 | Process for the Preparation of Thiazolopyrimidines | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | disclosed |
| US-20100217000-A1 | Process for the Preparation of Thiazolopyrimidines | ASTRAZENECA AB (SE) | 2010-08-26 | — | — | US | disclosed |
| EP-1711505-B1 | PROCESS FOR THE PREPARATION OF THIAZOLOPYRIMIDINES | ASTRAZENECA AB (SE) | 2010-06-23 | — | — | EP | disclosed |
| EP-1711505-B1 | PROCESS FOR THE PREPARATION OF THIAZOLOPYRIMIDINES | ASTRAZENECA AB (SE) | 2010-06-23 | — | — | EP | disclosed |
| EP-1543013-B1 | 5-[[(2,3-Difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one monosodium salt as CXCR2 antagonist | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| US-20080306262-A1 | Novel Compound | ASTRAZENECA AB, A SWEDISH CORPORATION | 2008-12-11 | — | — | US | disclosed |
| US-20080306262-A1 | Novel Compound | ASTRAZENECA AB, A SWEDISH CORPORATION | 2008-12-11 | — | — | US | disclosed |
| US-20080306262-A1 | Novel Compound | ASTRAZENECA AB, A SWEDISH CORPORATION | 2008-12-11 | — | — | US | disclosed |
| US-20070282103-A1 | Process for the Preparation of Thiazolopyrimidines | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | disclosed |
| US-20070282103-A1 | Process for the Preparation of Thiazolopyrimidines | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | disclosed |
| US-20070282103-A1 | Process for the Preparation of Thiazolopyrimidines | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | disclosed |
| US-20060100221-A1 | Novel compound | ASTRAZENECA AB (SE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090043097-A1 | Methods | CYP21A2, CYP17A1, HSD17B7 | CXCR2 2692/4885CX3CR1 4623/4885HTR1B 2485/4885 |
| US-20070282103-A1 | Process for the Preparation of Thiazolopyrimidines | TPMT, TYMP, DPYD | CXCR2 2764/4885CX3CR1 4576/4885HTR1B 2530/4885 |
| US-20060100221-A1 | Novel compound | SLC10A1, AVPR2, NPC1 | CXCR2 156/4885CX3CR1 2854/4885HTR1B 1153/4885 |
| US-20100217000-A1 | Process for the Preparation of Thiazolopyrimidines | TPMT, TYMP, DPYD | CXCR2 2645/4885CX3CR1 4479/4885HTR1B 1867/4885 |
| US-20080306262-A1 | Novel Compound | SLC10A1, AVPR2, NPC1 | CXCR2 156/4885CX3CR1 2854/4885HTR1B 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.